➤ 2021 ASCRS Annual Meeting update ➤ FDA approves new monofocal IOL ➤ First patient dosed in Phase 2 trial for investigational DED therapy ➤ Phase 2a trial initiated for add-on wet AMD therapy
➤ Topline results from Phase 3 studies for nAMD treatment ➤ Phase 2 trial of betamethasone treatment for cataract surgery pain and inflammation ➤ Fast Track designation given to therapy seeking to treat achromatopsia ➤ Topline data from Phase 1 trial of travoprost intracameral implant ➤ ASCRS Journal Club
➤ Success with first-in-human implant of new artificial cornea ➤ Launch of first longitudinal study for home OCT ➤ Enrollment complete for study evaluating treatment for Leber congenital amaurosis 10 ➤ Phase 1/2a trial for wet AMD treatment with suprachoroidal injection begins enrollment ➤ Fast Track designation issued for investigational dry AMD therapy
The COVID-19 pandemic hit home for our ophthalmology practices in March 2020, closing our offices and surgicenters for all but emergency patients for 10 weeks. This was the reality for many of us. There was an atmosphere of generalized concern bordering on panic in many locations due to a fear of the unknown.
For ASCRS members, and our ASCRS staff, 2020 has seen the ultimate examination of our resilience. It would be a tiresome and labored exercise to go through the process of recapping a year that we are all eager to put in the rearview mirror. “Unprecedented.” “Difficult times.” “We’re in this together.” Each word and phrase has become so ubiquitous they now trigger our brains to tune out whatever follows.
Elizabeth Yeu, MD, ASCRS Secretary, Richard Lindstrom, MD, ASCRS Member at Large, Douglas Rhee, MD, ASCRS Treasurer, Sumit “Sam” Garg, MD, Chair of ASCRS Young Eye Surgeons Committee, and Edward Holland, MD, ASCRS Program Chair, share thoughts on this unprecedented year.
When asked to write a reflection of the past year, I took a deep breath and sat down for a bit. So many emotions ran through me when I thought about this past year. It truly has been a roller coaster ride and a lesson in rapid adaptation.